Sarah S. Burns

1.5k total citations
28 papers, 468 citations indexed

About

Sarah S. Burns is a scholar working on Neurology, Hematology and Molecular Biology. According to data from OpenAlex, Sarah S. Burns has authored 28 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 10 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Sarah S. Burns's work include Neurofibromatosis and Schwannoma Cases (10 papers), Acute Myeloid Leukemia Research (7 papers) and Meningioma and schwannoma management (7 papers). Sarah S. Burns is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (10 papers), Acute Myeloid Leukemia Research (7 papers) and Meningioma and schwannoma management (7 papers). Sarah S. Burns collaborates with scholars based in United States, United Kingdom and Denmark. Sarah S. Burns's co-authors include Long‐Sheng Chang, Janet L. Oblinger, D. Bradley Welling, Reuben Kapur, Adrián Díaz, Matthew L. Bush, Abraham Jacob, Jie Huang, Elena M. Akhmametyeva and A. Douglas Kinghorn and has published in prestigious journals such as Blood, Cancer Research and Experimental Neurology.

In The Last Decade

Sarah S. Burns

27 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah S. Burns United States	15	167	128	122	85	72	28	468
Paulina B. Szklanna Ireland	13	137 0.8×	36 0.3×	36 0.3×	83 1.0×	137 1.9×	26	435
Ayad Al-Katib United States	9	59 0.4×	33 0.3×	66 0.5×	95 1.1×	24 0.3×	17	317
Pimjai Niparuck Thailand	12	77 0.5×	23 0.2×	67 0.5×	84 1.0×	160 2.2×	56	405
Ehab Saad Aldin United States	10	61 0.4×	31 0.2×	16 0.1×	36 0.4×	87 1.2×	18	302
Suzanne Hitchcock‐Bryan United States	8	177 1.1×	22 0.2×	55 0.5×	152 1.8×	242 3.4×	10	913
Wen‐Li Hwang Taiwan	12	60 0.4×	32 0.3×	29 0.2×	72 0.8×	150 2.1×	30	359
Yaning Yang China	13	210 1.3×	82 0.6×	77 0.6×	362 4.3×	11 0.2×	45	911
Lance Sieger United States	9	94 0.6×	46 0.4×	81 0.7×	166 2.0×	102 1.4×	16	545
Marion Sternbach Canada	10	126 0.8×	23 0.2×	64 0.5×	126 1.5×	263 3.7×	17	529
Monica Di Battista Italy	17	189 1.1×	73 0.6×	78 0.6×	222 2.6×	19 0.3×	40	810

Countries citing papers authored by Sarah S. Burns

Since Specialization

Citations

This map shows the geographic impact of Sarah S. Burns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah S. Burns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah S. Burns more than expected).

Fields of papers citing papers by Sarah S. Burns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah S. Burns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah S. Burns. The network helps show where Sarah S. Burns may publish in the future.

Co-authorship network of co-authors of Sarah S. Burns

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah S. Burns. A scholar is included among the top collaborators of Sarah S. Burns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah S. Burns. Sarah S. Burns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hord, Jeffrey M., Sarah S. Burns, Tobias Willer, et al.. (2025). Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan. Skeletal Muscle. 15(1). 1–1.

Russell, Nigel H., Abin Thomas, Robert K. Hills, et al.. (2023). MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial. Blood. 142(Supplement 1). 830–830. 4 indexed citations

Burns, Sarah S., et al.. (2022). Il-1r1 drives leukemogenesis induced by Tet2 loss. Leukemia. 36(10). 2531–2534. 17 indexed citations

Welling, D. Bradley, Katharine A. Collier, Sarah S. Burns, et al.. (2021). Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology. 6(5). 1008–1019. 24 indexed citations

Pasupuleti, Santhosh Kumar, Baskar Ramdas, Sarah S. Burns, et al.. (2021). Obesity-Induced Inflammation Co-Operates with Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutants to Promote Leukemia Development and Cardiovascular Disease. Blood. 138(Supplement 1). 1094–1094. 7 indexed citations

Baldan, Rossella, Penelope R. Cliff, Sarah S. Burns, et al.. (2021). Development and evaluation of a nanopore 16S rRNA gene sequencing service for same day targeted treatment of bacterial respiratory infection in the intensive care unit. Journal of Infection. 83(2). 167–174. 15 indexed citations

Ramdas, Baskar, Raghuveer Singh Mali, Lakshmi Reddy Palam, et al.. (2020). Driver Mutations in Leukemia Promote Disease Pathogenesis through a Combination of Cell-Autonomous and Niche Modulation. Stem Cell Reports. 15(1). 95–109. 10 indexed citations

Burns, Sarah S. & Reuben Kapur. (2020). Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia. Stem Cell Reports. 15(2). 279–291. 9 indexed citations

Burns, Sarah S. & Reuben Kapur. (2020). Putative Mechanisms Underlying Cardiovascular Disease Associated with Clonal Hematopoiesis of Indeterminate Potential. Stem Cell Reports. 15(2). 292–306. 4 indexed citations

10.

Chang, Long‐Sheng, Janet L. Oblinger, Sarah S. Burns, et al.. (2019). Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Molecular Cancer Therapeutics. 19(3). 731–741. 16 indexed citations

11.

Burns, Sarah S., Christine T. Dinh, Denise Yan, et al.. (2017). Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Molecular Cancer Therapeutics. 16(11). 2387–2398. 25 indexed citations

12.

Oblinger, Janet L., Sarah S. Burns, Jie Huang, et al.. (2017). Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology. 299(Pt B). 299–307. 23 indexed citations

13.

Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2016). A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 31(2). 310–317. 17 indexed citations

14.

Oblinger, Janet L., Sarah S. Burns, Elena M. Akhmametyeva, et al.. (2016). Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology. 18(9). 1265–1277. 27 indexed citations

15.

Burns, Sarah S. & Long‐Sheng Chang. (2016). Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma. Methods in molecular biology. 1427. 59–72. 8 indexed citations

16.

Spear, Samuel A., Sarah S. Burns, Janet L. Oblinger, et al.. (2013). Natural Compounds as Potential Treatments of NF2-Deficient Schwannoma and Meningioma. Otology & Neurotology. 34(8). 1519–1527. 23 indexed citations

17.

Burns, Sarah S., Elena M. Akhmametyeva, Janet L. Oblinger, et al.. (2012). Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2 -Deficient Meningioma Growth. Cancer Research. 73(2). 792–803. 38 indexed citations

18.

Bush, Matthew L., Sarah S. Burns, Janet L. Oblinger, et al.. (2012). Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors. Otology & Neurotology. 33(2). 244–257. 14 indexed citations

19.

Bush, Matthew L., Janet L. Oblinger, Jie Huang, et al.. (2011). AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13(9). 983–999. 64 indexed citations

20.

Griffiths, Gareth, Sarah S. Burns, Simon Noble, et al.. (2009). FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC Cancer. 9(1). 355–355. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact